

The Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEE'S PHARMACEUTICAL HOLDINGS LIMITED

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code : 950)

**GRANT OF SHARE OPTIONS UNDER
A SUBSIDIARY SHARE OPTION SCHEME**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board of Directors (the "Board") of Lee's Pharmaceutical Holdings Limited (the "Company") hereby announces that on 30 November 2012, CVie Therapeutics Company Limited ("CVie", a private company incorporated in the Cayman Islands with limited liability and is a subsidiary of the Company) has granted, subject to acceptance of the grantees, share options (the "Option") to certain eligible persons under share option scheme of CVie approved by the shareholders of the Company on 12 November 2012 to subscribe for 440,000 ordinary shares of US\$0.01 par value each of CVie (the "Shares"). Details of the Options granted are set out below:

Date of grant	30 November 2012
Exercise price of Options granted	US\$0.21 per Share
Market price of the Shares on the date of grant	Not applicable as the Shares are not listed
Details of grantees	The grantees are neither director, chief executive, substantial shareholders of the Company nor an associate of any of them.
Validity period of the Options	133,000 Options will be exercisable upon the success completion of Phase II study of either Rostafuroxin or Istaroxime but not more than ten years from the date of grant. 267,000 Options will be exercisable one year after the success completion of Phase II study of either Rostafuroxin or Istaroxime but not more than ten years from the date of grant. 40,000 will be exercisable during the period from 1 December 2014 to 30 November 2022.

By Order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 30 November 2012

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong, Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors; Mr. Mauro Bove is non-executive Director; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.